Using Urgotul dressing for the management of epidermolysis bullosa skin lesions.
OBJECTIVE
To evaluate the acceptability, tolerance and efficacy of Urgotul wound dressing in the management of epidermolysis bullosa (EB) skin lesions.


METHODS
This was an open-label uncontrolled clinical trial involving 20 patients (I I adults and nine children) with EB simplex or dystrophic EB. Patients were selected from the register of EB patients at the investigating centre and included if they presented with at least one skin lesion requiring management with a non-adherent wound dressing. Lesions were treated with the study dressing for a maximum of four weeks. All dressing changes, wound parameters, pain and effect on quality of life were recorded.


RESULTS
All patients completed the trial. Nineteen out of 20 wounds healed within 8.7 +/- 8.5 days. Overall, 11 patients (55%) considered that their quality of life had improved following use of the dressing, which was also reported to be pain free and 'very easy' or 'easy' to remove at most dressing changes. Nineteen out of 20 patients stated that they would use the study dressing to manage their lesions in future.


CONCLUSIONS
This study confirmed the very good acceptability and efficacy of Urgotul in the treatment of skin lesions in patients with EB.
Blanchet-Bardon
C
C
Department of Dermatology, Saint Louis Hospital, Paris, France. claudine.blanchet-bardon@sls.ap-hop-paris.fr
Bohbot
S
S
D000293:Adolescent; D000328:Adult; D047070:Bandages, Hydrocolloid; D003102:Colloids / Q000627:therapeutic use*; D004820:Epidermolysis Bullosa / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009779:Occlusive Dressings; D010577:Petrolatum / Q000627:therapeutic use*; D011446:Prospective Studies; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects
D003102:Colloids; D010577:Petrolatum